Michael Birnbaum received the Michelson Prize for Human Immunology and Vaccine Research 2020 to identify target antigens for HIV vaccine development. His team's novel methodology for studying immune cells' antigen recognition repertoire has multiple applications for other diseases, including cancer and COVID-19, and exemplifies the type of promising early career research supported by the prize.